Lung Cancer Screening Market Study Highlights How Industry Demand Is Evolving

The lung cancer screening market is poised for significant advancement in the coming years as new technologies and expanded programs aim to improve early detection and patient outcomes. With growing investments and innovations driving this space, the market landscape is evolving rapidly to meet increasing healthcare demands.

Projected Expansion and Market Size of the Lung Cancer Screening Market
The lung cancer screening market is expected to experience robust growth, reaching a value of $5.24 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 9.5%. Several factors are contributing to this upward trajectory, including the widespread adoption of AI-assisted diagnostic workflows, growth in population-based screening initiatives, enhanced focus on personalized risk assessments, rising investments in technologies for early cancer detection, and stronger healthcare policy support for screening programs. Key trends anticipated to shape the market include greater use of low-dose CT screening programs, increased integration of AI in imaging analysis, targeted screening for high-risk groups, expansion of preventive oncology efforts, and stronger emphasis on early lung cancer diagnosis.

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.33 billion in 2025 to $3.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to rising incidence of lung cancer among aging populations, increased awareness of early screening benefits, expansion of diagnostic imaging infrastructure, improvements in ct imaging technology, adoption of guideline-based screening protocols.

Download a free sample of the lung cancer screening market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27331&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Influencing the Lung Cancer Screening Market
The lung cancer screening industry features several prominent players driving innovation and growth. Notable companies in this sector include Abbott Laboratories Inc., Canon Inc., Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, Delfi Diagnostics Inc., Hologic Inc., Fujifilm Holdings Corporation, United Imaging Healthcare Co. Ltd., Samsung Medison Co. Ltd., Carestream Health Inc., Analogic Corporation, and Toshiba Medical Systems Corporation.

Collaborations to Enhance Early Detection in Lung Cancer Screening
In May 2025, Johnson & Johnson MedTech, a US-based healthcare technology firm, joined forces with Qure.ai to improve early lung cancer detection across India. Through this partnership, Johnson & Johnson MedTech sought to strengthen its AI-driven diagnostic tools and broaden access to early-stage lung cancer screening by launching AI-led Incidental Pulmonary Nodule (IPN) detection clinics in major Indian hospitals. Qure.ai, specializing in AI-powered medical imaging solutions for automated lung nodule detection, triage, and management, plays a critical role in this initiative to advance screening capabilities.

View the full lung cancer screening market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-screening-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovations Shaping the Future of Lung Cancer Screening
Market leaders are increasingly focusing on innovative technologies like normal flagging to enhance diagnostic precision, minimize false positives, and boost early identification of cancerous nodules. Normal flagging is an advanced feature that automatically flags scans with no abnormalities, enabling clinicians to prioritize cases requiring further examination. For example, in May 2025, South Korean medical technology company Lunit Inc. introduced the INSIGHT CXR4, a next-generation AI-powered chest X-ray analysis tool now CE MDR-certified for use across Europe. This solution helps radiologists improve diagnostic accuracy and workflow efficiency by detecting 12 chest abnormalities, including lung nodules, pneumonia, and acute bone fractures, and offers features such as current-prior image comparison to facilitate early disease detection and informed clinical decisions.

Detailed Segmentation Driving the Lung Cancer Screening Market
The lung cancer screening market is categorized into several key segments, including:
1) Diagnosis Type: Low Dose Spiral Computed Tomography (CT) Scan and Chest X-Ray
2) Cancer Type: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
3) Age Group: 50 and Older, and Below 50
4) End-User: Hospitals and Clinics, Diagnostic Centers, and Other End-Users

Further subsegments include:
- For Low Dose Spiral CT Scan: Screening, Diagnostic, and Follow-Up applications
- For Chest X-Ray: Posterior Anterior, Lateral, and Portable types

These classifications provide a comprehensive view of the market landscape and highlight critical areas contributing to lung cancer screening advancements.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.